Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Beyond BRCA: Exploring PARP Combinations in Prostate Cancer
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: March 30, 2021 Expiration: March 29, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer
Charles J. Ryan, MD
Neal D. Shore, MD, FACS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the medical need and rationale for PARP inhibitor–based combinations in prostate cancer with or without DNA damage repair alterations
  • Plan therapeutic strategies using PARP inhibitor–based combinations to improve outcomes for men with prostate cancer with or without DNA damage repair alterations
  • Evaluate the available clinical evidence on combination therapies including PARP inhibitors with androgen receptor–targeting agents or other therapies in metastatic CRPC
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director,
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Bayer, Clovis, Janssen, and Sanofi Genzyme; has received funds for research support from Clovis and the Prostate Cancer Foundation; has received fees for non-CME/CE services from Janssen; and has served in a study leadership position for Clovis.
Neal D. Shore, MD, FACS

Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, has disclosed that he has received consulting fees from AbbVie, Ambry, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Clovis, Dendreon, Exact Imaging, FerGene, Ferring, Foundation Medicine, Invitae, Janssen, MDx Health, Merck, Myovant, Myriad, NYMCX, Pfizer, Plat Q, Sanofi Genzyme, and Tolmar and fees for non-CME/CE services from Astellas, Bayer, Clovis, Janssen, and Pfizer.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, had no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 30, 2021, through March 29, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Beyond BRCA: Exploring PARP Combinations in Prostate Cancer
  • CME
  • MOC

Loading...
Learn about the many ongoing clinical trials for prostate cancer leveraging PARP inhibitors combined with a variety of agents including AR-directed therapy, immunotherapy, and other targeted agents.
Charles J. Ryan, MD
Neal D. Shore, MD, FACS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: March 30, 2021 Expiration: March 29, 2022

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on clinical trials of PARP inhibitor combinations in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

In this slideset from Clinical Care Options (CCO), experts present the rationale for PARP inhibitor combination therapies in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021

Downloadable slideset reviewing the latest evidence on PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: April 12, 2021

Charles J. Ryan, MD, reviews PARP inhibitor combination therapy clinical trials in prostate cancer and the evidence supporting these approaches from Clinical Care Options (CCO)

Charles J. Ryan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 12, 2021 Expired: April 11, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue